MYC and cholangiocarcinoma: On the other hand, hyperacetylation of c-Myc induced by administration of HDAC inhibitors destabilizes the protein [90], and deacetylation of c-Myc at lysine 323 by HDAC3 in cholangiocarcinoma cells protects c-Myc from ubiquitin-dependent proteolysis [91].